Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL)

Por Galanina, Natalie, Kurzrock, Razelle
Publicado no Cancer Biol Ther (2018)

Emerging role of checkpoint blockade therapy in lymphoma

Por Galanina, Natalie, Kline, Justin, Bishop, Michael R.
Publicado no Ther Adv Hematol (2017)

Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer

Por Adashek, Jacob J., Junior, Pedro Nazareth Aguiar, Galanina, Natalie, Kurzrock, Razelle
Publicado no J Immunother Cancer (2019)

Successful Treatment of HIV-associated Kaposi’s Sarcoma with Immune Checkpoint Blockade

Por Galanina, Natalie, Goodman, Aaron M., Cohen, Philip R., Frampton, Garrett M., Kurzrock, Razelle
Publicado no Cancer Immunol Res (2018)

Bone Metastasis as the Only Metastatic Site in a Patient with Pancreatic Cancer following Distal Pancreatectomy

Por Saif, Muhammad Wasif, Galanina, Natalie, Ravage-Mass, L., Kaley, Kristin, Cornfeld, Daniel, Lamb, Lynne, Chhieng, David
Publicado em 2010

Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib

Por Guo, Ailin, Lu, Pin, Galanina, Natalie, Nabhan, Chadi, Smith, Sonali M., Coleman, Morton, Wang, Y. Lynn
Publicado no Oncotarget (2015)

Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials

Por Galanina, Natalie, Bejar, Rafael, Choi, Michael, Goodman, Aaron, Wieduwilt, Matthew, Mulroney, Carolyn, Kim, Lisa, Yeerna, Huwate, Tamayo, Pablo, Vergilio, Jo-Anne, Mughal, Tariq I., Miller, Vincent, Jamieson, Catriona, Kurzrock, Razelle
Publicado no Cancers (Basel) (2018)

University of Chicago Phase II Consortium Trial of Selumetinib (MEKi) Demonstrates Low Tolerability and Efficacy in Relapsed DLBCL

Por Galanina, Natalie, Smith, Sonali M., Liao, Chuanhong, Petrich, Adam, Libao, Bernadette, Gartenhaus, Ronald, Westin, Jason, Cohen, Kenneth S, Knost, James A., Stadler, Walter M., Doyle, Austin, Karrison, Theodore, Gordon, Leo, Evens, Andrew M.
Publicado no Br J Haematol (2017)

Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma

Por Lee, Jimmy, Zhang, Liang Leo, Wu, Wenjun, Guo, Hui, Li, Yan, Sukhanova, Madina, Venkataraman, Girish, Zhang, Hui, Alikhan, Mir, Lu, Pin, Guo, Ailin, Galanina, Natalie, Andrade, Jorge, Wang, Michael L., Wang, Y. Lynn
Publicado no Blood Adv (2018)

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL

Por Sharma, Shruti, Galanina, Natalie, Guo, Ailin, Lee, Jimmy, Kadri, Sabah, Van Slambrouck, Charles, Long, Bradley, Wang, Weige, Ming, Mei, Furtado, Larissa V., Segal, Jeremy P., Stock, Wendy, Venkataraman, Girish, Tang, Wei-Jen, Lu, Pin, Wang, Yue Lynn
Publicado no Oncotarget (2016)

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL

Por Kadri, Sabah, Lee, Jimmy, Fitzpatrick, Carrie, Galanina, Natalie, Sukhanova, Madina, Venkataraman, Girish, Sharma, Shruti, Long, Brad, Petras, Kristin, Theissen, Megan, Ming, Mei, Kobzev, Yuri, Kang, Wenjun, Guo, Ailin, Wang, Weige, Niu, Nifang, Weiner, Howard, Thirman, Michael, Stock, Wendy, Smith, Sonali M., Nabhan, Chadi, Segal, Jeremy P., Lu, Pin, Wang, Y. Lynn
Publicado no Blood Adv (2017)